论文部分内容阅读
目的观察添加拉莫三嗪（ＬＴＧ）治疗顽固性癫痫的疗效及安全性。方法对３３例顽固性癫痫患者采用添加ＬＴＧ治疗开放性自身对照临床试验。结果发作频度减少≥５０％１９例（５７．６％），发作频度减少２６％～４９％４例（１２．１％），Ｌｅｎｎｏｘ－Ｇａｓｔａｕｔ综合征７例，疗效较佳。对部分性发作和泛化性发作的有效率分别为６５．４％和８０．６％，但统计学上无显著差异。ＬＴＧ与不同药物合用疗效无明显差异。仅４例有头痛、头晕、复视等轻微副作用，均为合用卡马西平者，减量后消失。结论ＬＴＧ是一有效广谱抗癫痫药，能与常用抗癫痫药联合治疗。临床使用中应注意ＬＴＧ诱导的卡马西平毒性。
Objective To observe the efficacy and safety of adding lamotrigine (LTG) in patients with intractable epilepsy. Methods Thirty-three patients with intractable epilepsy were treated with LTG in an open-label self-controlled clinical trial. Results The frequency of episodes was reduced by ≥50% in 19 cases (57.6%), seizure frequency was reduced by 26% ~ 49% in 4 cases (12.1%) and Lennox-Gastaut syndrome in 7 cases. The effective rates for partial and generalized episodes were 65.4% and 80.6%, respectively, but there were no statistically significant differences. There is no significant difference between LTG and different drugs. Only 4 cases of headache, dizziness, diplopia and other minor side effects, are combined carbamazepine, after reduction disappeared. Conclusion LTG is an effective broad-spectrum antiepileptic drug which can be combined with commonly used antiepileptic drugs. LTG-induced carbamazepine toxicity should be noted in clinical use.